Supplementary Table 1.
Univariate and Multivariate Logistic Regression Analysis for a Low Humoral Response (<100 AU/mL) in LTRs After a Third SARS-CoV-2 Vaccination Based on the Anti-S RBD Immunoassay
| Univariate OR (95% CI) | P | Multivariate OR (95% CI) | P | |
|---|---|---|---|---|
| Age, y | 1.01 (0.98–1.05) | .419 | ||
| Age >65 years (n = 34/106) | 0.99 (0.38–2.60) | .993 | ||
| Female sex (n = 42/106) | 0.82 (0.32–2.07) | .672 | ||
| Time from 1st LT, y | 0.97 (0.91–1.02) | .239 | ||
| Vaccination <1 y post LT (n = 10/106) | 3.80 (1.01–14.42) | .049 | 8.00 (1.34–47.77) | .023 |
| BMI, kg/m2 | 0.99 (0.88–1.11) | .829 | ||
| BMI ≥30 kg/m2 (n = 13/99) | 0.99 (0.25–3.95) | .989 | ||
| Arterial hypertension (n = 80/106) | 4.84 (1.06–22.17) | .042 | 5.93 (0.90–39.22) | .065 |
| Diabetes mellitus (n = 22/106) | 1.71 (0.61–4.83) | .310 | ||
| eGFR, mL/min | 0.96 (0.94–0.99) | .001 | ||
| eGFR <45 mL/min (n = 33/106) | 6.69 (2.52–17.77) | < .001 | 4.72 (1.56–14.38) | .006 |
| HbA1c, % | 1.01 (0.57–1.79) | .978 | ||
| HbA1c >5.6%a (n = 42/88) | 0.89 (0.34–2.33) | .805 | ||
| Lymphocytes, billion/μL | 0.16 (0.06–0.46) | .001 | ||
| Lymphocytes <1.3/nLa (n = 52/106) | 6.13 (2.09–17.97) | .001 | 5.02 (1.53–16.42) | .008 |
| Immunosuppression | ||||
| CNI monotherapy (n = 21/106) | 0.48 (0.13–1.78) | .270 | ||
| CNI + prednisone (n = 7/106) | 1.32 (0.24–7.27) | .748 | ||
| CNI + MMF (n = 44/106) | 0.97 (0.39–2.42) | .947 | ||
| CNI + mTORi (n = 16/106) | 1.21 (0.35–4.21) | .762 | ||
| Tac trough level, μg/L (n = 71) | 1.06 (0.74–1.52) | .768 | ||
| CSA trough level, μg/L (n = 22) | 0.87 (0.73–1.04) | .127 | ||
| IS including MMF (n = 49/106) | 1.51 (0.61–3.73) | .368 | ||
| MMF >1 g/d (n = 11/106) | 2.01 (0.54–7.54) | .299 | ||
| IS including mTOR, μg/L (n = 25) | 1.46 (0.53–4.08) | .466 | ||
| mTORi trough level (continuous, n = 25) | 1.12 (0.64–1.98) | .693 | ||
| IS including prednisone (n = 20/106) | 1.08 (0.35–3.35) | .890 | ||
| IS inclusing MMF or mTORi (n = 74/106) | 2.00 (0.68–5.10) | .210 | ||
Note: Long version listing all the tested variables with a group size of at least 10% each of LTRs (n = 10) in the case of categorial variables.
Note: Boldface P values indicate statistical significance.
Anti-S RBD, Anti-SARS-CoV-2 receptor-binding domain; BMI, body mass index; CI, confidence interval; CSA, cyclosporin; CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; IS, immunosuppression; LD, liver disease; LT, liver transplantation; LTR, liver transplant recipient; MMF, mycophenolate mofetil; mTORi, mammalian target of rapamycin inhibitor; OR, odds ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; Tac, tacrolimus.
Median of overall LT cohort.